We are live on ! Find out more
RDY icon

Dr. Reddy's Laboratories

228 hedge funds and large institutions have $1.5B invested in Dr. Reddy's Laboratories in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 86 increasing their positions, 75 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 75

0.06% less ownership

Funds ownership: 12.88%12.82% (-0.06%)

6% less funds holding

Funds holding: 243228 (-15)

7% less capital invested

Capital invested by funds: $1.62B → $1.5B (-$120M)

33% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 39

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

91% less call options, than puts

Call options by funds: $3K | Put options by funds: $35K

Holders
228
Holders Change
-15
Holders Change %
-6.17%
% of All Funds
2.99%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
26
Increased
86
Reduced
75
Closed
39
Calls
$3K
Puts
$35K
Net Calls
-$32K
Net Calls Change
-$16K
Name Holding Trade Value Shares
Change
Change in
Stake
QCG
26
Quadrant Capital Group
Ohio
$5.75M +$2.09M +145,259 +55%
Bank of America
27
Bank of America
North Carolina
$5.7M -$6.65M -461,848 -53%
DZ Bank
28
DZ Bank
Germany
$5.59M
VPIM
29
Vanguard Personalized Indexing Management
California
$4.91M +$817K +56,760 +19%
PAMS
30
Pinpoint Asset Management (Singapore)
$4.76M +$4.9M +340,497 New
QCM
31
Quantinno Capital Management
New York
$4.45M +$1.2M +83,606 +36%
Invesco
32
Invesco
Georgia
$4.39M +$869K +60,404 +24%
Citigroup
33
Citigroup
New York
$4.01M +$174K +12,063 +4%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$3.89M -$1.29M -89,865 -24%
AAM
35
Augustine Asset Management
Florida
$3.49M -$20.9K -1,449 -0.6%
AIM
36
Artemis Investment Management
United Kingdom
$3.36M +$1.51M +105,092 +78%
US Bancorp
37
US Bancorp
Minnesota
$3.21M +$463K +32,197 +16%
HF
38
HRT Financial
New York
$2.71M +$2.79M +193,921 New
VA
39
Vident Advisory
Georgia
$2.7M +$54.6K +3,792 +2%
LNWWM
40
Laird Norton Wetherby Wealth Management
California
$2.69M -$21.1K -1,468 -0.8%
ZIG
41
Zurich Insurance Group
Switzerland
$2.68M +$439K +30,527 +19%
HSBC Holdings
42
HSBC Holdings
United Kingdom
$2.65M +$1.41M +97,884 +107%
AQR Capital Management
43
AQR Capital Management
Connecticut
$2.62M -$92.4K -6,420 -3%
Deutsche Bank
44
Deutsche Bank
Germany
$2.56M +$41.9K +2,915 +2%
Mariner
45
Mariner
Kansas
$2.56M -$153K -10,600 -5%
Cerity Partners
46
Cerity Partners
New York
$2.37M -$64K -4,450 -3%
CCM
47
Causeway Capital Management
California
$2.22M
Corient Private Wealth
48
Corient Private Wealth
Florida
$2.22M +$532K +36,959 +30%
Legal & General Group
49
Legal & General Group
United Kingdom
$2.04M
SEI Investments
50
SEI Investments
Pennsylvania
$2.04M +$315K +21,866 +18%

RDY Hedge Fund Activity: Q3 2025 in Review

228 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q3 2025, worth a combined $1.5B — down 7.4% from $1.62B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of RDY and 26 opened new positions — a net loss of 13 holders — while 75 trimmed existing stakes and 86 added.

The largest buyer was Morgan Stanley, adding an estimated $21.1M. The largest seller was Geode Capital Management, cutting an estimated $18.9M.

  • 228 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q3 2025, down from 243 in Q2 2025.
  • Funds reported $1.5B of Dr. Reddy's Laboratories stock for Q3 2025, down 7.4% quarter-over-quarter.
  • 26 funds opened new Dr. Reddy's Laboratories positions in Q3 2025 and 39 closed out, a net change of -13 holders.
  • The largest Dr. Reddy's Laboratories buyer in Q3 2025 was Morgan Stanley, an estimated $21.1M added.
  • The largest Dr. Reddy's Laboratories seller in Q3 2025 was Geode Capital Management, an estimated $18.9M sold.

Based on aggregated 13F filings for Q3 2025.